Attenuation of scopolamine-induced cognitive dysfunction by obovatol

[1]  Jae Woong Lee,et al.  Obovatol improves cognitive functions in animal models for Alzheimer’s disease , 2012, Journal of neurochemistry.

[2]  Dong Hyun Kim,et al.  The ameliorating effects of stigmasterol on scopolamine-induced memory impairments in mice. , 2012, European journal of pharmacology.

[3]  Jae Woong Lee,et al.  Obovatol attenuates LPS-induced memory impairments in mice via inhibition of NF-κB signaling pathway , 2012, Neurochemistry International.

[4]  S. Aid,et al.  Inhibition of NADPH oxidase promotes alternative and anti‐inflammatory microglial activation during neuroinflammation , 2012, Journal of neurochemistry.

[5]  I. Uriarte-Pueyo,et al.  Flavonoids as acetylcholinesterase inhibitors. , 2011, Current medicinal chemistry.

[6]  I. Shim,et al.  Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats. , 2011, Journal of microbiology and biotechnology.

[7]  N. Greig,et al.  Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons , 2011, PloS one.

[8]  G. Superti-Furga,et al.  After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. , 2011, Bioorganic & medicinal chemistry.

[9]  Jae-Hwang Jeong,et al.  Neurotrophic activity of obovatol on the cultured embryonic rat neuronal cells by increase of neurotrophin release through activation of ERK pathway. , 2010, European journal of pharmacology.

[10]  Hyoung‐Chun Kim,et al.  Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. , 2010, European journal of pharmacology.

[11]  K. Suk,et al.  Obovatol attenuates microglia‐mediated neuroinflammation by modulating redox regulation , 2010, British journal of pharmacology.

[12]  H. Okada,et al.  Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice , 2009, Brain Research.

[13]  S. Mandel,et al.  Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties , 2009, Genes & Nutrition.

[14]  Y. Yun,et al.  Neurite Outgrowth Effect of 4-O-methylhonokiol by Induction of Neurotrophic Factors Through ERK Activation , 2009, Neurochemical Research.

[15]  S. Nam,et al.  Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity , 2009, Journal of Natural Medicines.

[16]  T. Ahmed,et al.  Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease , 2009, Pharmacology Biochemistry and Behavior.

[17]  R. Vassar,et al.  The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease Pathophysiology* , 2008, Journal of Biological Chemistry.

[18]  C. Glabe,et al.  Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.

[19]  Yeong-Rim Kang,et al.  Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis. , 2008, Bioorganic & medicinal chemistry.

[20]  J. Hong,et al.  Anxiolytic-like effects of obovatol isolated from Magnolia obovata: Involvement of GABA/benzodiazepine receptors complex , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  R. Schliebs,et al.  Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein , 2006, International Journal of Developmental Neuroscience.

[22]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[23]  R. Quirion,et al.  Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.

[24]  C. C. Lin,et al.  Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis , 2001, Phytotherapy research : PTR.

[25]  J. Growdon,et al.  Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[26]  J. Growdon,et al.  The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease , 2000, Annals of neurology.

[27]  T. Deacon,et al.  Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system , 1998, Neuroreport.

[28]  R. Nitsch,et al.  Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. , 1997, Life sciences.

[29]  E. Giacobini,et al.  Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex , 1993, Neuropharmacology.

[30]  E. Giacobini,et al.  Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum , 1993, Neuropharmacology.

[31]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[32]  S. M. Stahl,et al.  The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man , 1988, Journal of psychopharmacology.

[33]  N. Butters,et al.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. , 1986, Behavioral and neural biology.

[34]  R. Petersen,et al.  Scopolamine induced learning failures in man , 1977, Psychopharmacology.

[35]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[36]  V. Guillén,et al.  Cholinesterase inhibitors in the treatment of Alzheimer's disease , 2013 .

[37]  R. Quirion,et al.  Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. , 2002, Progress in neurobiology.

[38]  E. Mutschler,et al.  WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties. , 1993, Life sciences.